P067/132 Cerebral vasospasm treatment using comaneci device – registry study

Introduction

Subarachnoid haemorrhage (SAH) can result in cerebral vasospasms and delayed cerebral ischemia, which contribute significantly to morbidity and mortality. The effectiveness of endovascular treatment for this condition is still a subject of debate. However, the adjustable neck-bridging device Comaneci (Rapid Medical, Yokneam, Israel) may offer a safe and effective alternative to balloon angioplasty.

Aim of Study

The Comaneci Registry Trial is the first multicentre registry designed to evaluate the clinical and radiologic safety and efficacy of Comaneci in angioplasty of cerebral vasospasm in a standardized manner in patients with severe cerebral vasospasm after SAH.

Methods

All patients with severe vasospasm (>50%) in digital subtraction angiography (DSA) after aneurysmatic SAH treated with the Comaneci device as first-line therapy are included and evaluated through an angiographic vessel-by-vessel analysis using a 4-level scale as primary endpoint. All vessel-segments in anterior and posterior circulation up to M3-,A3- and P2-level are eligible for angioplasty with Comaneci. Clinical outcome is assessed with National Institutes of Health Stroke Scale (NIHSS) and modified Rankin Scale mRS.

Results

Although the study is still ongoing, the preliminary findings have demonstrated the safety and effectiveness of the treatment for vasospasm with Comaneci as a first-line angioplasty device.

Conclusion

The Comaneci device has the potential to serve as a first-line device for providing therapeutic benefit to patients with SAH and vasospasm. However, future prospective trials are required.

Disclosure of Interest

Nothing to disclose